Intracellular antibodies (Intrabodies) for gene therapy of infectious diseases

Annual Review of Microbiology

Volumn 51, Issue , 1997, Pages 257-283

  Rondon, Isaac J ^a   Marasco, Wayne A ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

AIDS; Gene therapy; HIV 1; Intrabodies; Intracellular immunization; Single chain antibodies

Indexed keywords

CAPSID PROTEIN; INTEGRASE; MATRIX PROTEIN; REV PROTEIN; TRANSACTIVATOR PROTEIN; VIRUS ANTIBODY;

ANTIBODY PRODUCTION; ANTIVIRAL ACTIVITY; GENE THERAPY; GENETIC ENGINEERING; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; VIRUS PATHOGENESIS;

ANTIBODY FORMATION; CYTOPLASM; GENE PRODUCTS, REV; GENE PRODUCTS, TAT; GENE THERAPY; HIV ANTIBODIES; HIV ANTIGENS; HIV ENVELOPE PROTEIN GP160; HIV INFECTIONS; HIV INTEGRASE; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; NUCLEOCAPSID PROTEINS;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; MIRIDAE;

EID: 0030818332     PISSN: 00664227     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.micro.51.1.257     Document Type: Review

References (155)

1. Akamatsu Y, Cole MS, Tso JY, Tsurushita N. 1993. Construction of a human Ig combinatorial library from genomic V segments and synthetic CDR3 fragments. J. Immunol. 151:4651-59
2. Amit AG, Mariuzza RA, Phillips SEV, Poljak RJ. 1986. Three-dimensional structure of an antigen-antibody complex at 2, 8 Å resolution. Science 233:747-53
3. Baltimore D. 1988. Intracellular immunization. Nature 335:395-96
4. Barr PJ, Tomei LD. 1994 Apoptosis and its role in human disease. Bio/Technology 12:487-93
5. Beerli RR, Weis W, Hynes NE. 1994. Intracellular expression of single chain antibodies reverts ErbB-2 transformation. J. Biol. Chem. 269:23931-36
6. Bess JW Jr, Powell PJ, Issaq HJ, Schumack LJ, Grimes MK, et al. 1992. Tightly bound zinc in human immunodeficiency virus Type 1. Human T-cell leukemia virus Type 1, and other retroviruses. J. Virol. 66:840-47
7. Biocca S, Neuberger MS, Cattaneo A. 1990. Expression and targeting of intracellular antibodies in mammalian cells. EMBO J. 9:101-8
8. Biocca S, Pierandrei-Amaldi P, Campion N, Cattaneo A. 1994. Intracellular immunization with cytosolic recombinant antibodies. Bio/Technology 12:396-99
9. ras single chain Fv fragments inhibits meiotic maturation of xenopus oocytes. Biochem. Biophys. Res. Commun. 197:422-27
10. Bird RE, Hardman KD, Jacobson JW, Johnson S, Kaufman BM, et al. 1988. Single-chain antigen-binding proteins. Science 242:423-26
11. Biswas DK, Salas TR, Wang F, Ahlers CM, Dezube BJ, Pardee AB. 1995. A Tat-induced auto-up-regulatory loop for superactivation of the human immunodeficiency virus type 1 promoter. J. Virol. 69:7437-44
12. Boldin MP, Goncharov TM, Goltsev YV, Wallach D. 1996. Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1- and TNF receptor-induced cell death. Cell 85:803-15
13. Bole DG, Hendershot LM, Kearney JF. 1986. Posttranslational association of immunoglobulin heavy chain binding protein with nascent heavy chains in nonsecreting and secreting hybridomas. J. Cell Biol. 102:1558-66
14. Brady HJM, Miles CG, Pennington DJ, Dzierzak EA. 1994. Specific ablation of human immunodeficiency virus Tat-expressing cells by conditionally toxic retroviruses. Proc. Natl. Acad. Sci. USA 91:365-69
15. Brenner MK, Rill DR, Holladay MS, Heslop HE, Moen RC, et al. 1993. Gene marking to determine whether autologous marrow infusion restores long-term haemopoiesis in cancer patients. Lancet 342:1134-37
16. Brinkman U, Reiter Y, Jung SH, Lee B, Pastan I. 1993. A recombinant immunotoxin comparing a disulfide-stabilized Fv fragment. Proc. Natl. Acad. Sci. USA 90:7538-42
17. Bryant M, Ratner L. 1990. Myristoylation-dependent replication and assembly of human immunodeficiency virus 1. Proc. Natl. Acad. Sci. USA 87:523-27
18. Bukrinsky MI, Haggerty S, Dempsey MP, Sharova N, Adzhubei A, et al. 1993. A nuclear localization signal within HIV-1 matrix protein that governs infection of non-dividing cells. Nature 365:666-69
19. Bukrinsky M, Sharova N, Stevenson M. 1993. Human immunodeficiency virus Type 1 2-LTR circles reside in a nucleoprotein complex which is different from the preintegration complex. J. Virol. 67:6863-65
20. Buonaguro L, Barillari G, Chang HK, Bohan CA, Kao V, et al. 1992. Effects of the human immunodeficiency virus Type 1 Tat protein on the expression of inflammatory cytokines. J. Virol. 66:7159-67
21. Buonaguro L, Buonaguro FM, Giraldo G, Ensoli B. 1994. The human immunodeficiency virus type 1 Tat protein transactivates tumor necrosis factor beta gene expression through a TAR-like structure. J. Virol. 68:2677-82
22. Burton DR, Barbas CF III, Persson MAA, Koenig S, Chanock RM, Lerner RA. 1991. A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals. Proc. Natl. Acad. Sci. USA 88:10134-37
23. Bushman FD, Fujiwara T, Craigie R. 1990. Retroviral DNA integration directed by HIV integration protein in vitro. Science 249:1555-58
24. Carlson JR. 1988. A new means of inducibly inactivating a cellular protein. Mol. Cell. Biol. 8:2638-46
25. Carroll WL, Mendel E, Levy S. 1988. Hybridoma fusion cell lines contain an aberrant Kappa transcript. Mol. Immunol. 25:991-95
26. Chen J, Yang Q, Yang A-G, Marasco WA, Chen S-Y. 1996. Intra- and extra-cellular immunization against HIV-1 infection with lymphocytes transduced with an AAV vector expressing a human anti-gp120 antibody gene. Hum. Gene Ther. 7:1515-25
27. Chen M, Garon C, Papas T. 1980. Native ribonucleoprotein is an efficient transcriptional complex of avia myeloblastosis virus. Proc. Natl. Acad. Sci. USA 77:1296-300
28. Chen SY, Khouri Y, Bagley J, Marasco W. 1994. Combined intra- and extra-cellular immunization against human immunodeficiency virus type 1 infection with a human anti-gp120 antibody. Proc. Natl. Acad. Sci. USA 91:5932-36
29. Choe H, Farzan M, Sun Y, Sullivan N, Rollins B, et al. 1996. The β-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 85:1135-48
30. Chothia C, Lesk AM, Tramontano A, Levitt M, Smith-Gill SJ, et al. 1989. Conformations of immunoglobulin hypervariable regions. Nature 342:877-83
31. Clackson T, Hoogenboom HR, Griffiths AD, Winter A. 1991. Making antibody fragments using phage display libraries. Nature 352:624-28
32. Clavel F, Hoggan MD, Willey RL, Strebel K, Martin MA, Repaske R. 1989. Genetic recombination of human immunodeficiency virus. J. Virol. 63:1455-59
33. Crise B, Rose JK. 1992. Human immunodeficiency virus Type 1 glycoprotein precursor retains a CD4-p56 complex in the endoplasmic reticulum. J. Virol. 66:2296-301
34. Dalgleish AG, Beverleym PC, Clapham PR, Crawford DH, Greaves MF, Weiss RA. 1984. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature 312:763-67
35. Deng HK, Liu R, Ellmeier W, Choe S, Unutmaz D, et al. 1996. Identification of a major co-receptor for primary isolates of HIV-1. Nature 381:661-66
36. Deshane J, Loechel F, Conry RM, Siegal GP, King CR, Curiel DT. 1994. Intra-cellular single-chain antibody directed against erbB2 down-regulates cell surface erbB2 and exhibits 1 selective anti-proliferative effect in erbB2 overexpressing cancer cell lines. Gene Ther. 1:332-37
37. Dickson C, Eisenman R, Fan H, Hunter E, Reich N. 1985. Protein biosynthesis and assembly. See Ref. 150, pp. 513-648
38. Doranz BJ, Rucker J, Yi Y, Smyth RJ, Samson M, et al. 1996. A dual-tropic primary HIV-1 isolate that uses fusin and the β-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell 85:1149-58
39. + cells is mediated by the chemokine receptor CC-CKR-5. Nature 381:667-73
40. Duan L, Bagasra O, Laughlin MA, Oakes JW, Pomerantz RJ. 1994. Potent inhibition of human immunodeficiency virus type 1 replication by an intracellular anti-Rev single-chain antibody. Proc. Natl. Acad. Sci. USA 91:5075-79
41. Duan L, Pomerantz RJ. 1994. Elimination of endogenous aberrant kappa chain transcripts from sp2/0-derived hybridoma cells by specific ribozyme cleavage: utility in genetic therapy of HIV-1 infections. Nucleic Acids Res. 22:5433-38
42. Duan L, Zhang H, Oakes JW, Bagasra O, Pomerantz RJ. 1994. Molecular and virological effects of intracellular anti-rev single-chain variable fragments on the expression of various human immunodeficiency virus-1 strains. Hum. Gene Ther. 5:1315-24
43. Duan L, Zhu M, Bagasra O, Pomerantz RJ. 1995. Intracellular immunization against HIV-1 infection of human T lymphocytes, utility of anti-rev single-chain variable fragments. Hum. Gene Ther 6:1561-73
44. Duke GM, Hoffman MA, Palmenberg AC. 1992. Sequence and structural elements that contribute to efficient encephalomyocarditis virus RNA translation. J. Virol. 66:1602-9
45. Dul JL, Argon Y. 1990. A single amino acid substitution in the variable region of the light chain specifically blocks immunoglobulin secretion. Proc. Natl. Acad. Sci. USA. 87:8135-39
46. Elroy-Stein O, Fuerst TR, Moss B. 1989. Cap-independent translation of mRNA conferred by encephalomyocarditis virus 5' sequence improves the performance of the vaccinia virus/bacteriophage T7 hybrid expression system. Proc. Natl. Acad. Sci. USA 86:6126-30
47. Engelman A, Englund G, Orenstein JM, Martin MA, Craigie R. 1995. Multiple effects of mutations in human immunodeficiency virus Type 1 integrase on viral replication. J. Virol. 69:2729-36
48. Engelman A, Hickman AB, Craigie R. 1994. The core and carboxyl-terminal domains of the integrase protein of human immunodeficiency virus Type 1 each contribute to nonspecific DNA binding. J. Virol. 68:5911-17
49. Erlichman C, Kerr IG. 1985. Antineoplastic drugs. In Principles of Medical Pharmacology, ed. H Kalant, WHE Roschlau, EM Sellers, 4:699-710
50. Fath I, Schweighoffer F, Rey I, Multon M-C, Boiziau J, et al. 1994. Cloning of a Grb2 isoform with apoptotic properties. Science 264:971-74
51. Feng Y, Broder CC, Kennedy PE, Berger EA. 1996. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 272:872-77
52. Frankhauser C, Izaurralde E, Adachi Y, Wingfield P, Laemmli UK. 1991. Specific complex of human immunodeficiency virus type 1 Rev and nucleolar B23 proteins: dissociation by the Rev response element. Mol. Cell. Biol. 11:567-75
53. Fritz CC, Zapp ML, Green MR. 1995. A human nucleoporin-like protein that specifically interacts with HIV Rev. Nature 376:530-33
54. Gatignol A, Buckler-White A, Beckhout B, Jeang K-T. 1991. Characterization of a human TAR RNA-binding protein that activates the HIV-1 LTR. Science 251:1597-600
55. Glockshuber R, Malia M, Pfitzinger I, Pluckthun A. 1990. A comparison of strategies to stabilize immunoglobulin Fv-fragments. Biochemistry 29(6):1362-67
56. Gottlinger HG, Sodroski JG, Haseltine WA. 1989. Role of capsid precursor processing and myristylation in morphogenesis and infectivity of HIV-1. Proc. Natl. Acad. Sci. USA 86:5781-85
57. Graus-Porta D, Beerli RR, Hynes NE. 1995. Single-chain antibody-mediated intracellular retention of ErbB-2 impairs Neu differentiation factor and epidermal growth factor signaling. Mol. Cell. Biol. 15(3):1181-91
58. Griffiths AD, Malmqvist M, Marks JD, Bye JM, et al. 1993. Human anti-self antibodies with high specificity from phage display libraries. EMBO J. 12:725-34
59. Hauber J, Malim MH, Cullen BR. 1989. Mutational analysis of the conserved basic domain of human immunodeficiency virus tat protein. J. Virol. 63(3):1181-87
60. Hendershot L, Bole D, Köhler G, Kearney JF. 1987. Assembly and secretion of heavy chains that do not associate postranslationally with immunoglobulin heavy chain-binding protein. J. Cell Biol. 104:761-67
61. Hiatt A, Cafferkey R, Bowdish K. 1989. Production of antibodies in transgenic plants. Nature 342:76-78
62. Hinkula J, Rosen J, Sundqvist V-A, Stigbrand T, Wahren B. 1990. Epitope mapping of the HIV-1 Gag region with monoclonal antibodies. Mol. Immunol. 27:395-403
63. Hoxie JA, Alpers JD, Rackowski JL, Huebner K, Haggarty BS, et al. 1986. Alterations in T4 (CD4) protein and MRNA synthesis in cells infected with HIV. Science 234:1123-27
64. Huse WD, Sastry L, Iverson SA, Kang AS, Alting-Mees M, et al. 1989. Generation of a large combinatorial library of the immunoglobulin repertoire in phage lambda. Res. Article 246:1275-81
65. Huston JS, Levinson D, Mudgett-Hunter M, Tai M-S, et al. 1988. Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. Proc. Natl. Acad. Sci. USA 85:5879-83
66. Jacks T, Power MD, Masiarz FR, Luciw PA, Barr PJ, Varmus HE. 1988. Characterization of ribosomal frameshifting in HIV-1 gag-pol expression. Nature 331:280-83
67. Jespers LS, Roberts A, Mahler SM, Winter G, Hoogenboom HR. 1994. Guiding the selection of human antibodies from phage display repertoires to a single epitope of an antigen. Bio/Technology 12:899-903
68. Jiang W, Venugopal K, Gould EA. 1995. Intracellular interference of tick-borne flavivirus infection by using a single-chain antibody fragment delivered by recombinant sindbis virus. J. Virol. 69:1044-49
69. Johnson MS, McClure MA, Feng D-F, Gray J, Doolittle RF. 1986. Computer analysis of retroviral pol genes: assignment of enzymatic functions to specific sequences and homologies with nonviral enzymes. Proc. Natl. Acad. Sci. USA 83:7648-52
70. Jones SD, Porter-Brooks J, Eberhardt B, Chen S-Y, Mhashilkar A, et al. 1995. Gene therapy for HIV using intracellular antibodies. J. Cell Biol. 21A:395
71. Julian K-CM, Hiatt A, Hein M, Vine ND, Wang F, et al. 1995. Generation and assembly of secretory antibodies in plants. Science 268:716-19
72. Kabat EA, Wu TT. 1991. Identical V region amino acid sequences and segments of sequences in antibodies of different specificities. J. Immunol. 147:1709-19
73. Kalderon D, Richardson WD, Markham AF, Smith AE. 1994. Sequence requirements for nuclear localisation of SV40 large-T antigen. Nature 311:33-38
74. Kalderon D, Roberts BL, Richardson WD, Smith AE. 1984. A short amino acid sequence able to specify nuclear location. Cell 39:499-509
75. Kalland K-H, Szilvay AM, Brokstad KA, Saetrevik W, Haukenes G. 1994. The human immunodeficiency virus type 1 Rev protein shuttles between the cytoplasm and nuclear compartments. Mol. Cell. Biol. 14:7436-44
76. Kalland K-H, Szilvay AM, Langhoff E, Kaukenes G. 1994. Subcellular distribution of human immunodeficiency virus type 1 Rev and colocalization of Rev with RNA splicing factors in a speckled pattern in the nucleoplasm. J. Virol. 68:1475-85
77. Kaloff CR, Haas IG. 1995. Coordination of immunoglobulin chain folding and immunoglobulin chain assembly is essential for the formation of functional IgG. Immunity 6:629-37
78. Kaplan AH, Swanstrom R. 1991. Gag proteins are processed in two cellular compartments. Proc. Natl. Acad. Sci. USA 88:4528-32
79. Kashanchi F, Piras G, Rodonovich MF, Duvall JF, Fattaey A, et al, 1994. Direct interaction of human TFIID with the HIV-1 transactivator tat. Nature 367:295-99
80. Kotin RM. 1994. Prospects for the use of adeno-associated virus as a vector for human gene therapy. Hum. Gene Ther. 5:793-801
81. 3 encoding oligonucleotide. Bio/Technology 19:700-2
82. Laspia MF, Rice AP, Mathews MB. 1989. HIV-1 Tat protein increases transcriptional initiation and stabilizes elongation. Cell 59:282-92
83. Lederman MM. 1995. Host-directed and immune-based therapies for human immunodeficiency virus infection. Ann. Intern. Med. 122(3):218-22
84. Levin R, Mhashilkar AM, Dorfman T, Bukovsky A, Zani C, et al. 1997. Inhibition of early and late events of the HIV-1 replication cycle by cytoplasmic Fab intrabodies against the matrix protein. Mol. Med. 2:96-110
85. Levy JA. 1989. HIV and the pathogenesis of AIDS. JAMA 261:2997-3006
86. Levy-Mintz P, Duan L, Zhang H, Hu B, Dornadula G, et al. 1996. Intra-cellular expression of single-chain variable fragments to inhibit early stages of the viral life cycle by targeting human immunodeficiency virus Type 1 integrase. J. Virol. 70:8821-32
87. Liu J, Perkins ND, Schmid RM, Nabel GJ. 1992. Specific NF-kB subunits act in concert with Tat to stimulate human immunodeficiency virus type 1 transcription. J. Virol. 66:3883-87
88. Liu R, Paxton WA, Choe S, Ceradini D, Martin SR, et al. 1996. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 86:367-77
89. Luo Y, Yu H, Peterlin BM. 1994. Cellular protein modulates effects of human immunodeficiency virus type 1 rev. J. Virol. 68:3850-56
90. Maciejewski JP, Weichold FF, Young NS, Cara A, Zella D, et al. 1995. Intracellular expression of antibody fragments directed against HIV reverse transcriptase prevents HIV infection in vitro. Nat. Mag. 1:667-73
91. Malim MH, Bohnlein S, Hauber J, Cullen BR. 1989. Functional dissection of the HIV-1 Rev transactivator-derivation of a trans-dominant repressor of Rev function. Cell 58:205
92. Malim MH, Hauber J, Fenrick R, Cullen BR. 1988. Immunodeficiency virus rev tram-activator modulates the expression of the viral regulatory genes. Nature 335:181-83
93. Malim MH, Tiley LS, McCarn DF, Rusche JR, Hauber J, Cullen BR. 1990. HIV-1 structural gene expression requires binding of the Rev trans-activator to its RNA target sequence. Cell 60:675-83
94. Marasco WA. 1995. Intracellular antibodies (intrabodies) as research reagents and therapeutic molecules for gene therapy. Immunotechnology 1:1-19
95. Marasco WA, Bagley J, Zani C, Posner M, Cavacini L, et al. 1992. Characterization of the cDNA of a broadly reactive neutralizing human anti-gp120 monoclonal antibody. J. Clin. Invest. 90:1467-78
96. Marasco WA, Haseltine WA, Chen SY. 1993. Design, intracellular expression, and activity of a human anti-human immunodeficiency virus type 1 gp120 single-chain antibody. Proc. Natl. Acad. Sci. USA 90:7889-93
97. Marciniak RA, Garcia-Blanco MA, Sharp PA. 1990. Identification and characterization of a HeLa nuclear protein that specifically binds to the trans-activation-response (TAR) element of human immunodeficiency virus. Proc. Natl. Acad. Sci. USA 87:3624-38
98. Marks JD, Griffiths AD, Malmqvist M, Clackson TP, Bye JM, Winter G. 1992. By-passing immunization: building high affinity human antibodies by chain shuffling. Bio/Technology 10:779-83
99. Marks JD, Hoogenboom HR, Bonnert TP, McCafferty J, Griffiths AD, Winter G. 1991. By-passing immunization human antibodies from V-gene libraries displayed on phage. J. Mol. Biol. 222:581-97
100. McCafferty J, Griffiths AD, Winter G, Chiswell DJ. 1990. Phage antibodies: filamentous phage displaying antibody variable domains. Lett. Nat. 348:552-54
101. McGregor DP, Molloy PE, Cunningham C, Harris WJ. 1994. Spontaneous assembly of bivalent single chain antibody fragments in Escherichia coli. Mol. Immunol. 31:219-26
102. Melnick J, Argon Y. 1995. Molecular chaperones and the biosynthesis of antigen receptors. Immunol. Today 16:243-50
103. Melnick J, Aviel S, Argon Y. 1992. The endoplasmic reticulum stress protein GRP94, in addition to BiP, associates with unassembled immunoglobulin chains. J. Biol. Chem. 267:21303-6
104. Melnick J, Dul JL, Argon Y. 1994. Sequential interaction of the chaperones BiP and GRP94 with immunoglobulin chains in the endoplasmic reticulum. Nature 370:373-75
105. Meyer BB, Malim MH. 1994. The HIV-1 Rev trans-activator shuttles between the nucleus and the cytoplasm. Genes Dev. 8:1538-47
106. Mhashilkar MA, Bagley J, Chen SY, Szilvay AM, Heiland DG, Marasco WA. 1995. Inhibition of HIV-1 Tat-mediated LTR transactivation and HIV-1 infection by anti-Tat single chain intrabodies. EMBO J. 14:1542-51
107. Munroe S, Pelham HRB. 1987. A C-terminal signal prevents secretion of luminal ER proteins. Cell 48:899-97
108. Muzio M, Chinnaiyan AM, Kischkel FC, O'Rourke K, Shevchenko A, et al. 1996. FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex. Cell 85:817-27
109. Muzyczka N. 1992. Use of adeno-associated virus as a general transduction vector for mammalian cells. Curr. Top. Microbiol. Immunol. 158:97-129
110. Niedrig M, Hinkula J, Weigelt W, L'Age-Stenr J, Pauli G, et al. 1989. Epitope mapping of monoclonal antibodies against human immunodeficiency virus type 1 structural proteins by using peptides. J. Virol. 63:3525-28
111. Ohana B, Moore PA, Ruben SR, Southgate CD, Green MR, Rosen CA. 1993. The type 1 human immunodeficiency virus Tat binding protein is a transcriptional activator belonging to an additional family of evolutionarily conserved genes. Proc. Natl. Acad. Sci. USA 90:138-42
112. Olsen HS, Cochrane AW, Dillon PJ, Nalin CM, Rosen CA. 1990. Interaction of the human immunodeficiency virus type 1 rev protein with structured region in env mRNA is dependent upon multimer formation mediated through a basic stretch of amino acids. Genes Dev. 4:1357-65
113. Ørum H, Andersen PS, Øster A, Johansen LK, Riise E, et al. 1993. Efficient method for constructing comprehensive murine Fab antibody libraries displayed on phage. Nucleic Acids Res. 21:4491-98
114. Pantaleo G, Fauci AS. 1995. Apoptosis in HIV infection. Nat. Med. 1:118-20
115. Pantaleo G, Graziosi C, Fauci AS. 1993. New concepts in the immunopathogenesis of human immunodeficiency virus infection. N. Engl. J. Med. 328(5): 327-35
116. Park H, Davies MV, Langland JO, Chang H-W, Nam YS, et al. 1994. TAR RNA-binding protein is an inhibitor of the interferon-induced protein kinase PKR. Proc. Natl. Acad. Sci. USA 91:4713-17
117. Peliska JA, Balasubramanian S, Giedroc DP, Benkovic SJ. 1994. Recombinant HIV-1 nucleocapsid protein accelerates HIV-1 reverse transcriptase catalyzed strand transfer reactions and modulates RNase H activity. Biochemistry 33: 13817-23
118. Popovic M, Sarngadharan MG, Read E, Gallo RC. 1984. Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science 224:497-500
119. Posner MR, Hideshima T, Cannon T, Mukherjee M, Mayer KH, Byrn RA. 1991. An IgG human monoclonal antibody that reacts with HIV-1/gp 120, inhibits virus binding to cells, and neutralizes infection. J. Immunol. 146:4325-32
120. Poznansky MC, Foxall R, Ramstedt U, Coker R, Mhashilkar A, et al. 1996. Intra-cellular antibodies against Tat and gp120 inhibit the replication of HIV-1 in T-cells from HIV-infected individuals. Abstr. Int. AIDS Conf., 10th, Vancouver
121. Prats AC, Sarih L, Gabus C, Litvak S, Keith G, Darlix JL. 1988. Small finger protein of avian and murine retroviruses has nucleic acid annealing activity and positions the replication primer tRNA onto genomic RNA. EMBO J. 7:1777-83
122. Pugsley AP. 1989. In Protein Targeting, San Diego: Academic
123. Richardson JH, Marasco WA. 1995. Intracellular antibodies: development and therapeutic potential. Trends Biotechol. 13:306-10
124. Richardson JH, Sodroski JG, Waldmann TA, Marasco WA. 1995. Phenotypic knockout of the high-affinity human interleukin 2 receptor by intracellular single-chain antibodies against the subunit of the receptor. Proc. Natl. Acad. Sci. USA 92:3137-41
125. + T lymphocytes armed with universal T-cell receptors. Blond 84:2878-89
126. Roe TY, Reynolds TC, Yu G, Brown PO. 1993. Integration of murine leukemia virus DNA depends on mitosis. EMBO J. 12:2099-108
127. Rondon IJ, Marasco WA. 1996. Inhibition of HIV-1 replication by a sFv intrabody against the nucleocapsid, NCp7. IBC Annu. Int. Conf. Antibody Eng., 7th. Coronado, CA (Abstr.) Dec. 2-4
128. Ruben S, Perkins A, Purcell R, Joung K, Sai R, et al. 1989. Structural and functional characterization of human immunodeficiency virus tat protein. J. Virol. 63(1):1-8
129. Ruhl M, Himmelspach M, Bahr GM, Hammerschmid F, Jacksche H, et al. 1993. Eukaryotic initiation factor 5A is a cellular target of the human immunodeficiency virus type 1 Rev activation domain mediating trans-activation. J. Cell Biol. 123:1309-20
130. Sarver N, Cantin EM, Chang PS, Zaia JA, Ladne PA. 1990. Ribozymes as potential anti-HIV-1 therapeutic agents. Science 247: 1222-25
131. Sastry KJ, Reddy RHR, Pandita R, Totpal K, Aggarwall BB. 1990. HIV-1 Tat gene induces tumor necrosis factor-β (Lymphotoxin) in a human B-lympho-blastoid cell line. J. Biol. Chem. 265:20091-93
132. Schier R, Bye J, Apell G, McCall A, Adams GP, et al. 1996. Isolation of high-affinity monomeric human anti-c-erfcB-2 single chain Fv using affinity-driven selection. J. Mol. Biol. 255:28-43
133. Shaheen F, Duan L, Zhu M, Bagasra O, Pomerantz RJ. 1996. Targeting human immunodeficiency virus Type 1 reverse transcriptase by intracellular expression of single-chain variable fragments to inhibit early stages of the viral life cycle. J. Virol. 70:3392-400
134. Sheng N, Erickson-Viitranen S. 1994. Cleveage of p15 in vitro by HIV-1 protease is RNA dependent. J. Virol. 68:6207-14
135. Shukla RR, Kimmel PL, Kumar A. 1994. Human immunodeficiency virus type 1 Rev-responsive element RNA binds to host cell-specific proteins. J. Virol. 68:2224-29
136. Siomi H, Shida H, Maki M, Hatanaka M. 1990. Effects of a highly basic region of human immunodeficiency virus Tat protein on nucleolar localization. J. Virol. 64:1803-7
137. Smith AE. 1995. Viral vectors in gene therapy. Annu. Rev. Microbiol. 49:807-38
138. Sodroski J, Goh WC, Rosen C, Dayton A, Terwilliger E, Haseltine WA. 1986. A second post-transcriptional trans-activator gene required for HTLV-III replication. Nature 321:412-17
139. Sodroski J, Goh WC, Rosen C, Tartar A, Portetelle D, et al. 1986. Replication and cytopathic potential of HTLV-III/LAV with sor gene deletions. Science 231:1549-53
140. Spearman P, Wang J-J, Vander Heyden N, Ratner L. 1994. Identification of human immunodeficiency virus type 1 gag protein domains essential to membrane binding and particle assembly. J. Virol. 68:3232-42
141. Sullenger BA, Gallardo HF, Ungers GE, Gilboa E. 1991. Analysis of trans-acting response decoy RNA-mediated inhibition of human immunodeficiency virus type 1 transactivation. J. Virol. 65(12):6811-16
142. Taviadoraki P, Benvenuto E, Trinca S, De Martinis D, Cattaneo A, Galeffi P. 1993. Transgenic plants expressing a functional single-chain Fv antibody are specifically protected from virus attack. Nature 366:469-72
143. Thompson CB. 1995. Apoptosis in the pathogenesis and treatment of disease. Science 267:1456-62
144. Varmus H. 1988. Retroviruses. Science 240:1427-35
145. Varmus HE, Swanstrom R. 1985. Replication of retroviruses. See Ref. 150, pp. 75-134 (Suppl.)
146. Vaughan TJ, Williams AJ, Pritchard K, Osbourn JK, Pope AR, et al. 1996. Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library. Nat. Biotech. 14:309
147. von Schwedler U, Kornbluth RS, Trono D. 1994. The nuclear localization signal of the matrix protein of human immunodeficiency virus type 1 allows the establishment of infection in macrophages and quiescent T lymphocytes. Proc. Natl. Acad. Sci. USA 91:6992-96
148. Ward ES, Güssow D, Griffiths AD, Jones PT, Winter G. 1989. Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli. Nature 341:544-46
149. Wang B, Ugen KE, Srikantan V, Agadjanyan MG, Dang K, et al. 1993. Gene inoculation generates immune responses against human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. USA 90: 4156-60
150. Weiss R, Teich N, Varmus H, Coffin J, eds. 1985. RNA Tumor Virus. Cold Spring Harbor, NY: Cold Spring Harbor Lab.
151. Westendorp MO, Li-Weber M, Frank RW, Krammer PH. 1994. Human immunodeficiency virus type 1 Tat unregulates interleukin-2 secretion in activated T cells. J. Virol. 68:4177-85
152. Winter G, Milstein C. 1991. Man-made antibodies. Nature 349:293-99
153. Wu Y, Duan L, Zhu M, Hu B, Kubota S, et al. 1996. Binding of intracellular anti-Rev single chain variable fragments to different epitopes of human immunodeficiency virus type 1 Rev: variations in viral inhibition. J. Virol. 70:3290-97
154. Zhou H, Fisher RJ, Papas TS. 1994. Optimization of primer sequences for mouse scFv repertoire display library construction. Nucleic Acids Res. 22:888-89
155. Zhou W, Parent LJ, Wills JW, Resh MD. 1994. Identification of a membrane-binding domain within the amino terminal region of human immunodeficiency virus type 1 gag protein which interacts with acidic phospholipids. J. Virol. 68:2556-69